Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 791

1.

The role of combination medical therapy in benign prostatic hyperplasia.

Greco KA, McVary KT.

Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Review.

PMID:
19002123
2.

A review of combination therapy in patients with benign prostatic hyperplasia.

McVary KT.

Clin Ther. 2007 Mar;29(3):387-98. Review.

PMID:
17577460
3.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
4.
5.

Finasteride for benign prostatic hyperplasia.

Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review.

PMID:
20927745
6.

Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.

Miner M, Rosenberg MT, Perelman MA.

Clin Ther. 2006 Jan;28(1):13-25. Review.

PMID:
16490576
8.
10.

Current role for combination therapy in male LUTS.

Chung DE, Kaplan SA.

Arch Esp Urol. 2010 Jun;63(5):323-32. Review. English, Spanish.

PMID:
20587837
11.

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.

Gallegos PJ, Frazee LA.

Pharmacotherapy. 2008 Mar;28(3):356-65. doi: 10.1592/phco.28.3.356. Review.

PMID:
18294115
12.

Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.

Plosker GL, Goa KL.

Pharmacoeconomics. 1997 Feb;11(2):184-97. Review.

PMID:
10165827
13.
14.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.

Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Review.

PMID:
21726934
15.

5alpha-reductase inhibitors: what role should they play?

Kaplan SA.

Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70. Review.

PMID:
11750255
16.
17.

Benign prostatic hyperplasia progression and its impact on treatment.

Djavan B, Waldert M, Ghawidel C, Marberger M.

Curr Opin Urol. 2004 Jan;14(1):45-50. Review.

PMID:
15091050
18.

Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.

Tarter TH, Vaughan ED Jr.

Curr Pharm Des. 2006;12(7):775-83. Review.

PMID:
16515494
19.

Comorbid LUTS and erectile dysfunction: optimizing their management.

Kaminetsky J.

Curr Med Res Opin. 2006 Dec;22(12):2497-506. Review.

PMID:
17265598
20.

Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Rosen RC, Giuliano F, Carson CC.

Eur Urol. 2005 Jun;47(6):824-37. Epub 2005 Jan 5. Review.

PMID:
15925080

Supplemental Content

Support Center